Vitamin D–AMP Axis in Host Defense Against Fungal Infections

Why It Matters

With invasive fungal infections rising and resistance eroding existing therapies, leveraging vitamin D‑driven host defenses offers a novel adjunctive strategy. Understanding the limits of direct vitamin D₃ use guides safe, evidence‑based clinical applications.

Key Takeaways

• Vitamin D induces LL‑37 and β‑defensins, boosting fungal killing.
• Optimal serum 25(OH)D linked to lower invasive candidiasis risk.
• Direct vitamin D₃ antifungal activity requires supraphysiologic, unsafe doses.
• Rodent models lack human CAMP VDRE, limiting preclinical translation.

Pulse Analysis

Invasive fungal diseases now account for millions of infections and over two million deaths worldwide, driven by expanding immunocompromised populations and the alarming spread of azole‑ and echinocandin‑resistant strains. Conventional antifungals face a dwindling pipeline, prompting researchers to explore host‑directed therapies that can augment the body’s own defenses without adding selective pressure on pathogens. Vitamin D, long recognized for its role in calcium homeostasis, has emerged as a promising immunomodulator capable of stimulating antimicrobial peptide (AMP) production, offering a complementary avenue to combat these high‑mortality infections.

The active hormone 1,25‑dihydroxyvitamin D₃ binds the vitamin D receptor (VDR) in epithelial and immune cells, forming a VDR‑RXR complex that activates vitamin‑D response elements (VDREs) in genes such as CAMP, which encodes the cathelicidin precursor hCAP‑18/LL‑37. This peptide disrupts fungal membranes, promotes autophagy, and recruits immune cells. Human β‑defensins are similarly up‑regulated when VDR signaling intersects with NF‑κB pathways during inflammation. Mechanistic studies demonstrate dose‑dependent AMP induction, while animal models show reduced fungal burden in vitamin‑D‑replete mice. Notably, the CAMP VDRE is primate‑specific, explaining why standard rodent experiments may underestimate human relevance.

Clinical data remain limited but suggest that sufficient serum 25‑hydroxyvitamin D correlates with lower rates of invasive candidiasis and improved outcomes in aspergillosis. Randomized trials of vitamin D supplementation as an adjunct have yielded mixed results, largely due to heterogeneous dosing and baseline deficiencies. Direct use of vitamin D₃ as an antifungal agent is constrained by the micromolar concentrations needed for in‑vitro inhibition, which exceed safe systemic levels and risk hypercalcemia. Future research should prioritize well‑designed trials of vitamin‑D analogs that selectively boost AMP pathways, biomarker‑guided dosing, and exploration of combination regimens that pair host‑directed immunity with existing antifungals. Such strategies could fill a critical gap in the fight against drug‑resistant fungal pathogens.